Alzheimer’s Drug Poses a Dilemma for the F.D.A.

If the agency approves it, aducanumab would be the first new Alzheimer’s treatment since 2003. Patients are desperate for new options, but some scientists say there isn’t enough evidence it works. View original article Contributor: Pam Belluck and Rebecca Robbins

Why A.I. Should Be Afraid of Us

Because benevolent bots are suckers. Plus, racism in medical journals, the sperm-count “crisis” and more in the Friday edition of the Science Times newsletter. View original article Contributor: Alan Burdick